Eva González‐Barca

7.1k total citations · 1 hit paper
161 papers, 3.3k citations indexed

About

Eva González‐Barca is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Eva González‐Barca has authored 161 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 115 papers in Pathology and Forensic Medicine, 82 papers in Genetics and 79 papers in Oncology. Recurrent topics in Eva González‐Barca's work include Lymphoma Diagnosis and Treatment (114 papers), Chronic Lymphocytic Leukemia Research (76 papers) and Viral-associated cancers and disorders (35 papers). Eva González‐Barca is often cited by papers focused on Lymphoma Diagnosis and Treatment (114 papers), Chronic Lymphocytic Leukemia Research (76 papers) and Viral-associated cancers and disorders (35 papers). Eva González‐Barca collaborates with scholars based in Spain, United States and Italy. Eva González‐Barca's co-authors include Jordi Carratalà, A. Fernández‐Sevilla, Eva Domingo‐Doménech, Antonio Salar, Francesc Gudiol, A Grañena, Juan‐Manuel Sancho, Alberto Fernández de Sevilla, Gilles Salles and Eugènia Abella and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Eva González‐Barca

152 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

2020 324 citations Eva González‐Barca, Günter Fingerle‐Rowson et al. profile →

Peers

Countries citing papers authored by Eva González‐Barca

Since Specialization

Citations

This map shows the geographic impact of Eva González‐Barca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva González‐Barca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva González‐Barca more than expected).

Fields of papers citing papers by Eva González‐Barca

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva González‐Barca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva González‐Barca. The network helps show where Eva González‐Barca may publish in the future.

Co-authorship network of co-authors of Eva González‐Barca

This figure shows the co-authorship network connecting the top 25 collaborators of Eva González‐Barca. A scholar is included among the top collaborators of Eva González‐Barca based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva González‐Barca. Eva González‐Barca is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Developing New Strategies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma 2023 ·Journal of Clinical Medicine ·Eva González‐Barca	5
2	Lenalidomide in combination with R‐ESHAP in patients with relapsed or refractory diffuse large B‐cell lymphoma: A phase 2 study from GELTAMO 2023 ·British Journal of Haematology ·Alejandro Martı́n, Mónica Baile, Guillermo Rodríguez‐Domínguez, Iván Dlouhy, Juan‐Manuel Sancho, Isidro Jarque, Eva González‐Barca, Antonio Salar, (unknown), Carlos Grande, Juan Bergua, Santiago Montes‐Moreno, Alba Redondo, Anna Enjuanes, Elı́as Campo, Armando López‐Guillermo, Dolores Caballero	0
3	Front-line fludarabine-cyclophosphamide-rituximab (FCR) in 110 patients with chronic lymphocytic leukaemia (CLL): real-life experience with long-term outcomes, toxicities and responses to second-line therapies 2022 ·International Journal of Hematology ·Ana Carla Oliveira, (unknown), Christelle Ferrá, (unknown), (unknown), Maite Encuentra, Eva Domingo‐Doménech, (unknown), David Gallardo, Josep‐María Ribera, Josep Sarrà, Anna Sureda, Eva González‐Barca	1
4	Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma 2021 ·Blood Advances ·Michael Dickinson, Javier Briones, Alex F. Herrera, Eva González‐Barca, Nilanjan Ghosh, Raúl Córdoba, Sarah C. Rutherford, Eirini Bournazou, Emily Labriola–Tompkins, (unknown), (unknown), Jurriaan Brouwer‐Visser, Katharina Lechner, Barbara J. Brennan, Eveline Nüesch, Mark DeMario, Dominik Rüttinger, Martin Kornacker, Martin Hutchings	29
5	Clonal relationship in multisited mucosa‐associated lymphoid tissue lymphomas: a single‐centre experience 2020 ·British Journal of Haematology ·(unknown), Fina Climent, (unknown), Dolors Colomer, Mònica López‐Guerra, Mar Varela, (unknown), Clara Maluquer, Santiago Mercadal, Ana Carla Oliveira, (unknown), Xavier Matías‐Guiu, Eva González‐Barca, Anna Sureda, Eva Domingo‐Doménech	0
6	Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients 2020 ·Annals of Hematology ·(unknown), Eva González‐Barca, Francisco Capote, José Gómez‐Codina, Carlos Panizo, Antonio Salar, Juan‐Manuel Sancho, Andrés López, Javier Briones, Andrés Muñoz, Maite Encuentra, Santiago Mercadal, Eva Domingo‐Doménech, Alberto Fernández de Sevilla	8
7	Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma 2019 ·Blood ·Deborah A. Katz, Michael P. Chu, Kevin A. David, Catherine Thiéblemont, Nicholas Morley, (unknown), Yuqi Chen, James Kalabus, Joan Morris, Abraham Anderson, Ariel A. Avilion, Eva González‐Barca	20
8	m7FLIPI and targeted sequencing in high‐risk follicular lymphoma 2019 ·Hematological Oncology ·Marc Sorigué, (unknown), Santiago Mercadal, Gustavo Tapia, Fina Climent, Laia Perez‐Roca, (unknown), Eva Domingo‐Doménech, (unknown), José‐Tomás Navarro, Eva González‐Barca, Lurdes Zamora, Josep‐María Ribera, Anna Sureda, (unknown), Juan‐Manuel Sancho	3
9	Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome 2017 ·Hematological Oncology ·Marc Sorigué, Santiago Mercadal, Sara Alonso, Rubén Fernández-Álvarez, Olga García, (unknown), Helena Pomares, Miguel Alcoceba, (unknown), (unknown), Eva González‐Barca, Alejandro Martı́n, Anna Sureda, Dolores Caballero, Josep‐María Ribera, Juan‐Manuel Sancho	11
10	Baseline PET-Derived Metabolic Tumor Volume Metrics Predict Progression-Free and Overall Survival in DLBCL after First-Line Treatment: Results from the Phase 3 GOYA Study 2017 ·Blood ·Lale Kostakoglu, Maurizio Martelli, Laurie H. Sehn, David Belada, (unknown), Neil Chua, Eva González‐Barca, Xiaonan Hong, Antonio Pinto, Yuankai Shi, Yoichi Tatsumi, Günter Fingerle‐Rowson, Andrea Knapp, Federico Mattiello, Tina Nielsen, Gila Sellam, (unknown), Umberto Vitolo, Marek Trněný	20
11	The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells through the upregulation of NOXA and synergizes with ibrutinib, 5-aminoimidazole-4-carboxamide riboside or venetoclax 2017 ·Haematologica ·Ana M. Cosialls, Helena Pomares, Daniel Iglesias‐Serret, (unknown), (unknown), Diana M. González‐Gironès, (unknown), Sara Preciado, Fernando Alberício, Rodolfo Lavilla, Gabriel Pons, Eva González‐Barca, Joan Gil	19
12	Aberrant Epstein-Barr virus antibody patterns and chronic lymphocytic leukemia in a Spanish multicentric case-control study 2015 ·Infectious Agents and Cancer ·Delphine Casabonne, Yolanda Benavente, Clàudia Robles, Laura Costas, Esther Alonso, Eva González‐Barca, Adonina Tardón, Trinidad Dierssen‐Sotos, (unknown), Marta Aymerich, Elı́as Campo, Gemma Castaño‐Vinyals, Núria Aragonés, Marina Pollán, Manolis Kogevinas, Hedy Juwana, Jaap M. Middeldorp, Sílvia de Sanjosé	2
13	Antibody Response to Merkel Cell Polyomavirus Associated with Incident Lymphoma in the Epilymph Case–Control Study in Spain 2012 ·Cancer Epidemiology Biomarkers & Prevention ·Clàudia Robles, (unknown), Delphine Casabonne, Eva González‐Barca, Ramón Bosch, Yolanda Benavente, Raphael P. Viscidi, Sílvia de Sanjosé	10
14	Effect of addition of rituximab to salvage chemotherapy on outcome of patients with diffuse large B-cell lymphoma relapsing after an autologous stem-cell transplantation 2010 ·Annals of Oncology ·(unknown), Alejandro Martı́n, E. Condé, Antonio Pascual, Inmaculada Heras, Rosario Varela, Javier de la Rubia, (unknown), José L. Díez‐Martín, Carlos Panizo, (unknown), María Pascual, (unknown), Eva González‐Barca, Marı́a Dolores Caballero	9
15	Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma 2009 ·Cancer ·(unknown), Carlos Panizo, (unknown), Guillermo Debén, Alberto Álvarez‐Larrán, Eva González‐Barca, Juan‐Manuel Sancho, María Jesús Peñarrubia, (unknown), José A. García-Vela	27
16	Multiplex ligation-dependent probe amplification for detection of genomic alterations in chronic lymphocytic leukemia. 2007 ·Molecular Cancer Therapeutics ·(unknown), Antonio F. Santidrián, Ana M. Cosialls, Daniel Iglesias‐Serret, Mercè de Frías, Javier Grau, (unknown), Eva González‐Barca, Gabriel Pons, Alícia Domingo, Joan Gil	9
17	Association of Human Leukocyte Antigen Haplotypes with Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation 2006 ·Transplantation ·Marion Subklewe, (unknown), Sylvain Choquet, Véronique Leblond, (unknown), Roland Hetzer, Lode J. Swinnen, Stephan Oertel, Matthias Papp‐Váry, Eva González‐Barca, Bouke G. Hepkema, Constanze Schoenemann, Jürgen May, Antonio Pezzutto, Hanno Riess	41
18	Lack of serological evidence for an association between simian virus 40 and lymphoma 2003 ·International Journal of Cancer ·Sílvia de Sanjosé, Keerti V. Shah, Eva Domingo‐Doménech, Eric A. Engels, Alberto Fernández de Sevilla, Tomás Álvaro, (unknown), (unknown), Eva González‐Barca, Raphael P. Viscidi	49
19	Autologous stem cell transplantation (ASCT) with immunologically purged progenitor cells in patients with advanced stage follicular lymphoma after early partial or complete remission: toxicity, follow-up of minimal residual disease and survival 2000 ·Bone Marrow Transplantation ·Eva González‐Barca, Alberto Fernández de Sevilla, (unknown), V. Romagosa, (unknown), Sílvia de Sanjosé, (unknown), J Petit, (unknown), A Grañena	9
20	Noninvasive mechanical ventilation in a patient with respiratory failure after hematopoietic progenitor transplantation 1998 ·Bone Marrow Transplantation ·Danny Omar Mendoza Marín, Eva González‐Barca, Eva Domingo, (unknown), A Grañena	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact